We are the pioneer in the development of global oligonucleotide drugs, committed to the development of RNA interference (RNAi) technology and industrialization of oligonucleotide drugs. We have established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization. We have built a globally integrated oligonucleotide drug development capability and have established a robust siRNA drug pipeline through independent innovation, covering cardiovascular, metabolic, renal， liver and other diseases, especially in the field of chronic disease treatment.
